H. Köppler - Concepedia

Author

H. Köppler

Also Known As

H Köppler, H Köppler, H. Koppler, H. Köppler, H. KÖPPLER, H. KÖPpler, H. Köppler, H. Köppler, Hubert Koppler, Hubert Köppler

127

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Philipps University of Marburg Praxis für Hämatologie und Onkologie Evangelisches Krankenhaus Hamm Institut für Versorgungsforschung in der Onkologie University Hospital Cologne

About

H. Köppler is an author at Philipps University of Marburg specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	991
2	Health Sciences	4	4	98
3	Cell Biology	3	3	71
4	Engineering	1	1	10
5	Hepatology	1	1	42

H. Köppler

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematology	2016	613
Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma Ulrich Kaiser, Irmgard Uebelacker, Ulrich Abel, Journal of Clinical Oncology	2002	139
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study) Barbara Eichhorst, Anna Maria Fink, Raymonde Busch, Blood	2014	117
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG) Rudolf Weide, H. Köppler, Jochen Heymanns, Leukemia & lymphoma/Leukemia and lymphoma	2007	97
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy Rudolf Weide, Jochen Heymanns, Annette Pandorf, Lupus	2003	87
Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study Rudolf Weide, Annette Pandorf, Jochen Heymanns, Leukemia & lymphoma/Leukemia and lymphoma	2004	66
Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG) Barbara Eichhorst, Anna‐Maria Fink, Raymonde Busch, Blood	2013	55
Ultrasound evaluation of hepatic and splenic microabscesses in the immunocompromised patient: Sonographic patterns, differential diagnosis, and follow‐up Christian Görg, R. Weide, W. B. Schwerk, Journal of Clinical Ultrasound Diagnostic MycologyMedical UltrasoundImmunologyImmunocompromised PatientPathology	1994	42
SUCCESSFUL TREATMENT OF CLOZAPINE INDUCED AGRANULOCYTOSIS WITH GRANULOCYTE‐COLONY STIMULATING FACTOR (G‐CSF) Rudolf Weide, H. Köppler, Jochen Heymanns, British Journal of Haematology PharmacologyMedicine	1992	42
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors Rudolf Weide, Stefan Feiten, Vera Friesenhahn, SpringerPlus	2014	42

Page 1